Evidence map›Paper›PMID 34739394›Full record

ArticleAging2021

Curcumol inhibits malignant biological behaviors and TMZ-resistance in glioma cells by inhibiting long noncoding RNA FOXD2-As1-promoted EZH2 activation.

Xuyang Lv, Jiangchuan Sun, Linfeng Hu, Ying Qian, Chunlei Fan, Nan Tian

Open access · hybridAbstract read
In one paragraph

Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. [Curcumol reverses temozolomide resistance in glioma cells by regulating the UTX/MGMT axis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Xuyang LvMolecular Medicine Institute, Life Science College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Jiangchuan SunMolecular Medicine Institute, Life Science College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Linfeng HuMolecular Medicine Institute, Life Science College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Ying QianMolecular Medicine Institute, Life Science College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Chunlei FanMolecular Medicine Institute, Life Science College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Nan TianMolecular Medicine Institute, Life Science College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Zhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, conventional treatment is not sufficient to improve the survival of glioma patients. Hence, adopting novel personalized treatment programs is imperative. Curcumol, a Chinese herbal medicine extract from the roots of

Indexed as

Drug Resistance, NeoplasmAntineoplastic Agents, AlkylatingCell Line, TumorCell ProliferationEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticGliomaHumansRNA, Long NoncodingSesquiterpenesSignal TransductionTemozolomideAntineoplastic Agents, AlkylatingcurcumolEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanlong non-coding RNA FOXD2-AS1, humanRNA, Long NoncodingSesquiterpenesTemozolomidecurcumolepigenetic modificationEZH2gliomalncRNAs

Identifiers

PMID34739394
PMCPMC8610140
OpenAlexW3154593485

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.